PARIS, France—Investigators designing ISAR-REACT 5, the first head-to-head trial of ticagrelor and prasugrel in ACS patients heading for revascularization, expected to prove that ticagrelor is ...
Among patients with ACS who undergo PCI, a prasugrel-based strategy is superior to one using ticagrelor in terms of all-cause death, MI, and stroke at 12 months, according to a prespecified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback